ClinicalTrials.gg
RecruitingNCT06244264Updated Jul 12, 2024

The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis

An interventional study of Autoblood transfusion in Spinal Metastases, Blood Transfusion Complication and Lung Cancer, sponsored by Guangdong Provincial People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-12.

Sponsored by Guangdong Provincial People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this single-center prospective randomized controlled trial is to test and compare the safety and effectiveness of autologous blood transfusion in spinal surgery for lung cancer spinal metastases. The main questions it aims to answer are:

  • Does autologous blood transfusion increase the incidence of new metastases?
  • Does autologous blood transfusion affect postoperative hemoglobin levels and the number of circulating tumor cells in the blood?
  • Can autologous blood transfusion reduce the rate of allogeneic transfusion during and after surgery for spinal metastases?
Read the detailed description

In this study, participants underwent standard open spinal decompression surgery, and when blood transfusion was needed, autologous blood transfusion or allogeneic blood transfusion was used. Participants will be patients with lung cancer spinal metastases. Investigators will use flow cytometry, immunohistochemistry, and tumor cell culture methods to measure the number of circulating tumor cells in the blood before and after autologous blood transfusion.

Investigators will compare participants who receive autologous blood transfusion with those who do not to observe if there are differences in:

  • The incidence of new metastases
  • The rate of allogeneic transfusion during and after surgery
  • Postoperative hemoglobin levels
  • The number of circulating tumor cells in the blood
  • The cost associated with transfusion
02

Conditions studied

  • Spinal Metastases
  • Blood Transfusion Complication
  • Lung Cancer
  • Surgery
  • Autologous Blood Transfusion
03

In context

Transfusion Reaction

56 studies on the registry are indexed under Transfusion Reaction; 12 are open to participants now.

This study's planned enrollment of 118 is above the median of 71 across 23 interventional studies indexed under Transfusion Reaction.

Browse Transfusion Reaction studies →

Lead sponsor

Guangdong Provincial People's Hospital is the lead sponsor of 237 studies on the registry; 102 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The age range is 18-75 years old;
  • The pathological diagnosis was lung cancer and spinal tumor;
  • Expected survival > 3 months, can tolerate surgery;
  • Unstable spine; And/or spinal cord nerve compression, nerve function; Progressive decline, palliative spinal open decompression surgery
  • Patients with intraoperative/postoperative \<90 g/L or other conditions requiring blood transfusion

Exclusion criteria

Exclusion Criteria:

  • Serious heart dysfunction or heart failure, diagnosed blood system diseases, coagulation disorders;
  • Severe renal insufficiency or need hemodialysis treatment;
  • Sepsis or septicemia;
  • Unable to obtain consent from the patient or family.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    Autoblood transfusion + leukocyte filter group

    In our department open surgery is considered as the standard procedure. The patients underwent open surgery, with autologous blood transfusion combined with a leukocyte filter. Blood transfusion based on bleeding during surgery.

    Procedure: Autoblood transfusion

  • No intervention
    Allogeneic blood transfusion group

    In our department open surgery is considered as the standard procedure. The patients receives open surgery with allogeneic blood transfusion. Blood transfusion based on bleeding during surgery.

Interventions

  • ProcedureAutoblood transfusion

    Through a negative pressure suction device, the patient's blood that flows out during surgery is collected into a blood storage filter. During the suction process, it is mixed with an appropriate anticoagulant and passed through multiple layers of filters. When the volume of recovered blood reaches a certain level, it is continuously (or intermittently) centrifuged. Using a high-speed centrifugal blood recovery tank, the red blood cells are separated, and the plasma, waste, cell fragments, anticoagulants, and harmful components are diverted into a waste bag. A large amount of saline is used to repeatedly wash, purify, and concentrate the red blood cells. Finally, the concentrated red blood cells are prepared into a 70% red blood cell suspension with saline and stored in a collection bag for transfusion back to the patients. Open surgery is considered as the standard procedure for metastatic spinal cord compression

06

What researchers measure

Primary outcomes

  1. Intraoperative and postoperative allogeneic blood transfusion rate

    The number of allogeneic blood transfusion patients (Intraoperative or postoperative )/ the total number of patients

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Number of circulating tumor cells in the blood

    Number of circulating tumor cells in the blood

    Time frame: within 30 days post-surgery

  2. Incidence of transfusion related adverse reactions

    the number of adverse reactions/ the total number of patients

    Time frame: within 14 days post-surgery

  3. occurence of new lesions

    the number of patients with occurence of new lesions / the total number of patients

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — After the research is completed, the data may be publicly shared depending on the outcome.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Dec 2025, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2024
First posted
Feb 6, 2024
StartActual
Mar 15, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2027
Last update
Jul 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06244264
Responsible party
Yu Zhang, PhD (Chief of Orthopedic Oncology, Guangdong Provincial People's Hospital) — Principal investigator
First posted
Feb 6, 2024
Start date
Mar 15, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 12, 2024

Study contacts

Yu Zhang, Ph.D.
Contact
luck_2001@126.com
8613602744495
Guoqing Zhong, M.D.
Contact
gqzhong@foxmail.com
8613417005047

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion